Saturday 17 October 2026 Export IDXX’s income statement to Excel — free account

IDEXX Laboratories, Inc.

IDEXX Laboratories, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, up 10.4% from fiscal 2024. In the quarter to June 2026, revenue grew 9.66%, EPS grew 17.2%, free cash flow grew 111.4% and total debt fell 14.3%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; revenue growth for ten consecutive years, operating cash flow growth for three.

560.36 13.18 +2.41%

Follow IDXX

Alert me

Market cap: $43.1B
P/E: 39.1×
Fwd P/E: 38.3×
Dividend yield: —
F-score: 8/9
Altman Z: 24.09
Beneish M: −2.50
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Insider Decisions trades per month

Total sells 37.66

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	1	—	—	5	1	—	—	—	—	—	1	—

Insider Ownership 0.60%

Capital & Financial Ratios $m

Market Cap 43,110.00

Revenue 4,553.22

Net Income 1,139.66

Free Cash Flow 1,237.09

Net Debt 252.93

Current Ratio 1.17

Debt/Equity 0.28

P/E ratio 39.10

Fwd P/E 38.30

P/S ratio 9.72

P/B ratio 27.44

Past 5Y EPS Growth 14.28%

This Y EPS Growth 12.82%

Next Y EPS Growth 13.54%

Next Y revenue growth 9.74%

Next 5Y EPS Growth 13.33%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/E against its own 10 years 6.93%

10-year low 10-year high

P/S against its own 10 years 44.08%

10-year low 10-year high

P/B against its own 10 years 17.69%

10-year low 10-year high

EV/Sales against its own 10 years 41.21%

10-year low 10-year high

EV/FCF against its own 10 years 2.14%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	454	288	180	197
Receivables	457	474	552	627
Inventory	380	382	378	392
Other	204	256	304	294
	1,495	1,400	1,414	1,509

	2023	2024	2025	Q'26
Payables	111	114	110	129
ST’ Debt	75	168	75	150
Other	—	—	—	—
	952	1,068	1,149	1,288

Compound Annual Growth %

	10y	5y	3y
Sales	10.39%	9.72%	8.52%
Cash Flow	18.21%	12.77%	29.59%
Earnings	18.62%	12.74%	15.98%
Book Value	0.00%	20.47%	38.16%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	1,141	1,217	—	—	—
’25	998	1,109	1,105	1,091	4,304
’24	964	1,004	976	954	3,898
’23	900	944	916	902	3,661
’22	837	861	842	829	3,367
’21	778	826	810	801	3,215
’20	626	638	722	721	2,707

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	266	347	—	—	—
’25	238	186	402	356	1,182
’24	199	248	220	262	929
’23	184	200	272	250	907
’22	115	66	189	173	543
’21	124	234	187	210	756
’20	28	208	193	219	648

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	232	321	—	—	—
’25	208	152	358	326	1,044
’24	91	215	192	223	798
’23	144	173	238	217	773
’22	73	36	151	124	384
’21	100	211	142	178	636
’20	(22)	184	174	205	540

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	3.47	4.27	—	—	—
’25	2.96	3.63	3.40	3.08	13.08
’24	2.81	2.44	2.80	2.62	10.67
’23	2.55	2.67	2.53	2.32	10.06
’22	2.27	1.56	2.15	2.05	8.03
’21	2.35	2.34	2.03	1.89	8.60
’20	1.29	1.72	1.69	2.01	6.71

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	63.48	113.92	157.53	176.11	168.65	455.23	317.06	372.50	398.50	356.14	Analyst estimates 2026–2028 Powerpack
	High	121.77	173.01	256.22	294.57	503.83	706.95	656.31	568.30	583.39	769.98
People
People	Employees	7,365	7,600	8,377	9,200	9,300	10,350	10,780	11,000	11,000	11,000
	Revenue/emp, $m	0.24	0.26	0.26	0.26	0.29	0.31	0.31	0.33	0.35	0.39
Income, $m
Income, $m	Revenue	1,775	1,969	2,213	2,407	2,707	3,215	3,367	3,661	3,898	4,304
	Gross margin, %	54.94	55.73	56.10	56.73	58.04	58.76	59.52	59.82	61.04	61.80
	EBT	322	381	458	522	662	903	860	1,061	1,110	1,324
	EBT margin, %	18.13	19.35	20.68	21.70	24.46	28.07	25.54	28.99	28.48	30.77
	Net income	222	263	377	428	582	745	679	845	888	1,059
	Depreciation	79	83	83	88	96	105	112	115	130	145
Per share, $
Per share, $	Revenue	19.79	22.43	25.48	27.95	31.72	37.74	40.27	44.07	47.26	53.51
	Earnings	2.47	3.00	4.34	4.97	6.82	8.74	8.12	10.17	10.77	13.17
	Cash flow	3.78	4.25	4.61	5.33	7.59	8.87	6.49	10.91	11.27	14.69
	Capex	(0.72)	(0.87)	(1.42)	(1.80)	(1.26)	(1.40)	(1.90)	(1.61)	(1.59)	(1.72)
	Free cash flow	3.06	3.38	3.19	3.53	6.33	7.46	4.59	9.30	9.68	12.98
	Book value	(1.21)	(0.61)	(0.11)	2.07	7.41	8.10	7.28	17.87	19.34	19.96
	Shares, m	90	88	87	86	85	85	84	83	82	80
Valuation, ×
Valuation, ×	P/E	47.42	52.60	42.96	52.65	73.40	75.34	50.00	53.85	38.39	51.33
	P/S	5.94	7.03	7.30	9.34	15.76	17.45	10.08	12.43	8.75	12.64
	P/B	0.00	0.00	0.00	126.46	67.42	81.31	55.77	30.65	21.37	33.89
	EV/Sales	6.06	7.10	7.52	9.72	15.95	17.67	10.28	12.49	8.83	12.71
	EV/FCF	39.23	47.16	60.54	78.85	79.91	89.94	90.09	59.95	47.74	57.16
Cash, $m
Cash, $m	Operating cash flow	339	373	400	459	648	756	543	907	929	1,182
	Capex	(65)	(77)	(123)	(155)	(108)	(120)	(159)	(134)	(131)	(138)
	Free cash flow	274	297	277	304	540	636	384	773	798	1,044
Balance, $m
Balance, $m	Working capital	(89)	(33)	(116)	(46)	480	192	(134)	544	332	265
	Total debt	1,204	1,261	1,000	1,003	908	850	769	698	618	450
	Net debt	812	789	877	913	525	706	657	244	329	270
	Shareholders’ equity	(108)	(54)	(9)	178	633	690	609	1,485	1,595	1,605
Returns, %
Returns, %	ROA	14.77	16.22	23.20	25.39	28.19	31.48	26.20	28.14	27.10	31.89
	ROIC	31.09	35.11	35.41	31.69	37.51	41.74	44.39	39.67	36.64	45.33
	ROE	(231.05)	(324.76)	(1,195.50)	507.40	143.54	112.62	104.58	80.74	57.66	66.20

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
NTRA Natera, Inc.	$58.4B	— (loss-making)	— (loss-making)	+37.71% (above 0%: growing)	n/m	−173.96% (below 0%: shrinking)	64.46%	(10.07%)	Compare
A Agilent Technologies, Inc.	$49.5B	34.0×	26.3×	+8.06% (above 0%: growing)	+8.47% (above 0%: growing)	+69.50% (above 0%: growing)	55.48%	23.64%	Compare
IQV IQVIA Holdings Inc.	$44.6B	32.8×	22.3×	+8.74% (above 0%: growing)	−0.65% (below 0%: shrinking)	+23.29% (above 0%: growing)	32.85%	11.58%	Compare
WAT Waters Corporation	$43.6B	109×	44.3×	+113.36% (above 0%: growing)	n/m	+750.00% (above 0%: growing)	44.62%	(5.23%)	Compare
IDXX IDEXX Laboratories, Inc.	$43.1B	39.1×	38.3×	+9.66% (above 0%: growing)	+17.21% (above 0%: growing)	+111.44% (above 0%: growing)	64.04%	34.98%
ILMN Illumina, Inc.	$40.5B	48.4×	34.7×	+9.44% (above 0%: growing)	−8.05% (below 0%: shrinking)	−18.27% (below 0%: shrinking)	66.44%	21.14%	Compare
MTD Mettler-Toledo International, Inc.	$32.8B	36.4×	25.5×	+4.48% (above 0%: growing)	+18.30% (above 0%: growing)	+33.01% (above 0%: growing)	63.29%	30.61%	Compare
DGX Quest Diagnostics Incorporated	$26.4B	24.6×	20.8×	+10.21% (above 0%: growing)	+14.74% (above 0%: growing)	+5.28% (above 0%: growing)	33.75%	15.08%	Compare
LH Labcorp Holdings Inc.	$26.4B	26.2×	19.0×	+5.78% (above 0%: growing)	+28.42% (above 0%: growing)	−42.01% (below 0%: shrinking)	29.80%	12.10%	Compare
Median of peers	$42.1B	34.0×	25.5×	+9.09%	+11.61%	+14.29%	50.05%	13.59%

All 52 Diagnostics & Research stocks →

IDEXX Laboratories, Inc. (IDXX) key facts

Strength: IDEXX Laboratories, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, up 10.4% from fiscal 2024.
Strength: Net income was $1.1 billion, or $13.17 per share (basic), a net margin of 24.6%.
IDEXX Laboratories, Inc. (IDXX) is a Diagnostics & Research company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, IDXX traded at $560.36, a market capitalization of $43.1 billion.
At that price the stock trades at 39.1× trailing-twelve-month earnings and 9.7× sales; its P/E is higher than 7% of its own readings over the past ten years.
Return on equity was 66.2% and debt-to-equity 0.28.
Its Piotroski F-score is 8 out of 9 and its Altman Z-score is 24.09 (safe zone) for fiscal 2025.